Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc       US6285301072

End-of-day quote. End-of-day quote Nasdaq - 03/04
55.605 USD   +0.31%
04/17DJTeva Pharmaceutical Considering Bid for Mylan
04/17DJTeva Pharmaceutical Considering Bid for Mylan -- Update
04/17 MYLAN NV : Comments on Recent Media Speculation
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Seeks To Overturn FDA's Provigil Decision

04/05/2012 | 01:10pm US/Eastern

Mylan Inc. (>> Mylan Inc.) said it is seeking to overturn a decision by the U.S. Food and Drug Administration that awarded Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) exclusivity for its generic version of Cephalon Inc.'s wakefulness drug Provigil.

The generic drug maker said Thursday it has filed a lawsuit against the FDA in the U.S. district court for the District of Columbia. Mylan is seeking an immediate court order entitling it to exclusivity as well as immediate approval for its abbreviated new drug application.

Mylan alleges Teva did not maintain valid certifications as a result of its acquisition last year of Cephalon and thus is not entitled to exclusivity based on patent certifications. Mylan also alleges that the FDA should have found Mylan as the sole first filer on one of the patents for Provigil.

Earlier Thursday, Teva said the FDA has decided that Teva is the sole first-to-file for both of Provigil's patents, which entitled the company to 180-day exclusivity. The FDA decided that Cephalon's launch of generic Provigil on March 29 triggered the exclusivity.

In October, the Federal Trade Commission required Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant in connection with Teva's acquisition of Cephalon. The FTC agreement also required Teva to enter a supply agreement that allows a competing firm, Par Pharmaceuticals Inc. (PRX), to sell a generic version of Provigil in 2012.

Teva expects Par Pharmaceuticals to launch a second generic product on April 6.

Mylan shares slipped 1.8% to $22.74 in recent trading. The stock is up 5.9% so far this year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Mylan Inc.
React to this article
Latest news on MYLAN INC
04/17DJTeva Pharmaceutical Considering Bid for Mylan
04/17DJTeva Pharmaceutical Considering Bid for Mylan -- Update
04/17 MYLAN NV : Comments on Recent Media Speculation
04/17DJTeva Pharmaceutical Considering Bid for Mylan
04/17 MYLAN NV : Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalati..
04/13 MYLAN NV : Notifies Perrigo of HSR Filing Regarding Proposed Acquisition
04/13 MYLAN NV : Settles Patent Litigation Related to Viagra®
04/12DJBig Deals Are A Big Deal
04/10 Goldman widens gap in deal rankings, notching up $119 billion in one week
04/09DJMARKET SNAPSHOT : U.S. Stocks: Futures Slip As Investors Digest Fed Minutes
Advertisement
Chart
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF